Treace Medical Concepts, Inc.
corporate_fare Company Profile
Treace Medical Concepts, Inc. (NASDAQ:TMCI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for TMCI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 7 rated 8 or above. Recent SEC coverage for TMCI spans 10-Q, 8-K, 4, DEF 14A.
Recent high-impact activity:
- Treace 10-Q: Q3 Revenue Down 4% to $48.3M, Cash Burn Narrows to $0.7M
- Treace Q3 Revenue Falls 4% to $48.3M, Adjusted EBITDA Turns Positive at $0.3M
- Treace Q3 Revenue Slips 4% but EBITDA Turns Positive, 2026 Loss Outlook Cut to $1M-$2M
- Treace's 5-Year Lapiplasty Data Shows 0.8% Recurrence, Boosting Clinical Case
- Treace Medical Launches SuperBite and Three Other Products, Full Rollout in Q3
Financial Snapshot
Short Interest & Short Volume
8.65 days to coverFINRA reported short interest of 1,791,040 shares in TMCI as of the October 30, 2026 settlement, a 6.9% decrease from the prior period — about 8.7 days to cover at its recent average daily volume. On November 20, 2026, 40.7% of TMCI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.